S
Stephan A. Grupp
Researcher at Children's Hospital of Philadelphia
Publications - 396
Citations - 44427
Stephan A. Grupp is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Chimeric antigen receptor & Transplantation. The author has an hindex of 77, co-authored 366 publications receiving 34450 citations. Previous affiliations of Stephan A. Grupp include University of Pennsylvania & St. Jude Children's Research Hospital.
Papers
More filters
Journal ArticleDOI
Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19
Michael Kalos,Farzana Nazimuddin,Jeffrey Finklestein,Minnal Gupta,Irina Kulikovskaya,David E Ambrose,Saar Gill,Simon F. Lacey,Zhaohui Zheng,J. Joseph Melenhorst,Bruce L. Levine,Noelle V. Frey,Stephan A. Grupp,David L. Porter,Carl H. June +14 more
TL;DR: Analysis of clinical data on the use of T cells engineered to express a Chimeric Antigen Receptor (CAR) that targets CD19 (CTL019) in patients with advanced treatment-refractory CLL and pediatric ALL demonstrates that CRs were accompanied with deep and sustained molecular remissions as assessed by the absence of the tumor specific clonotype defined in the enrollment samples.
Journal ArticleDOI
Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.
Nancy A. Kernan,Paul G. Richardson,Angela R. Smith,Brandon M. Triplett,Joseph H. Antin,Leslie Lehmann,Yoav H. Messinger,Wei Liang,Robin Hume,William Tappe,Robert J. Soiffer,Stephan A. Grupp +11 more
TL;DR: A post hoc analysis of nontransplant‐associated VOD/SOS patients treated with defibrotide initiated within 30 days of starting chemotherapy and followed for 70 days is presented.
Journal ArticleDOI
Cutting edge: Lymphoproliferation caused by Fas deficiency is dependent on the transcription factor eomesodermin.
Ichiko Kinjyo,Scott M. Gordon,Andrew M. Intlekofer,Kennichi C. Dowdell,Erin C. Mooney,Roberto Caricchio,Stephan A. Grupp,David T. Teachey,V. Koneti Rao,Tullia Lindsten,Steven L. Reiner +10 more
TL;DR: Although Eomes has critical physiological roles in the function and homeostasis of CD8+ T cells, overexpression of Eomes appears to enable pathological induction or expansion of unusual CD8-related T cell subsets, and antagonism of Eomers emerges as a therapeutic target for DN T cell ablation in ALPS.
Journal ArticleDOI
Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan failure.
Paul G. Richardson,Stephan A. Grupp,Antonio Pagliuca,Amrita Krishnan,Vincent T. Ho,Selim Corbacioglu +5 more
TL;DR: In vitro evidence suggests defibrotide may restore thrombotic-fibrinolytic balance at the endothelial level and protect endothelial cells in patients with hepatic veno-occlusive disease after hematopoietic stem cell transplantation.